A Phase 1, Three-Part Open-Label Drug-Drug Interaction Study in Healthy participants to Determine the Effects of Itraconazole on the Pharmacokinetics of JNT-517 (Victim) and the Effects of JNT-517 (Perpetrator) on the Pharmacokinetics of Midazolam and Pravastatin

Exclusion Criteria43

• Any acute or chronic medical condition that would prevent the participant from complying with
• the procedures or place the participant at risk if they participate in the study.
• Positive for hepatitis B or C or human immunodeficiency virus.
• Any history of malignancy in the last 5 years, excluding non-melanoma skin cancer.
• Any history of liver disease
• Any surgical or medical conditions that may affect study drug absorption, distribution,
• metabolism, or excretion.
• Creatinine clearance <90 mL/min by the Chronic Kidney Disease Epidemiology Collaboration
• (CKD-EPI) creatine equation.
• Received another investigational drug within 30 days or, if known, 5 half-lives of the
• investigational drug (whichever is longer).
• Alcohol consumption within 5 days of Check in and/or unwilling to abstain during the study.
• Has consumed herbal preparations/medications, including but not limited to St. John's wort, kava,
• ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, or ginseng,
• within 7 days prior to study drug dosing.
• Intake of nutritional supplements, juice, other foods or beverages that may affect the various drug
• metabolizing enzymes and transporters (eg, alcohol, grapefruit, starfruit, Seville oranges, or their
• products) are not permitted for 7 days before dosing and throughout the study.
• Smoker (defined as an individual who has used nicotine-containing products, including cigarettes
• and e-cigarettes) within the last 2 weeks prior to dosing and a positive cotinine test on Day –1.
• Consumption of caffeinated beverages or food within 72 hours prior to Check-in.
• Use or intend to use any prescription medications/products within 14 days prior to dosing, unless
• deemed acceptable by the Investigator (or designee), or use or intend to use any nonprescription
• medications/products including vitamins and minerals within 7 days prior to Check in, unless
• deemed acceptable by the Investigator (or designee).
• Use or intend to use slow release medications/products considered to still be active within 14
• days prior to Check in, unless deemed acceptable by the Investigator (or designee).
• Use of any medications that are inhibitors or inducers of cytochrome P450 (CYP)3A4 or
• inhibitors of the transporter P-glycoprotein (P-gp) within 4 weeks prior to randomization and
• unwilling and/or unable to avoid these medications throughout the treatment duration.
• Use of any medication that is a substrate of CYP3A4, or a substrate of the transporters P-gp,
• breast cancer resistance protein (BCRP), organic anion transporter 3 (OAT3), multidrug and toxin
• extrusion (MATE)1, or MATE2-K within 4 weeks prior to randomization and unwilling and/or
• unable to avoid these medications throughout the treatment duration.
• History of drug/alcohol abuse in the last year.
• Positive drug screen.
• Unable to tolerate oral medication.
• Allergy to JNT-517 or any component of the investigational product.
• Allergy to itraconazole (Part A), midazolam (Part B), or pravastatin (Part C)
• Previous exposure to JNT-517 in another clinical trial
• Received >50 mL of blood or plasma within 30 days of Screening or >500 mL of blood or plasma
• within 60 days of Screening.
• Blood donation of >500 mL within 56 days prior to Screening